Free Trial

Prelude Therapeutics (PRLD) Stock Forecast & Price Target

$6.20
0.00 (0.00%)
(As of 07/17/2024 ET)

Prelude Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 3 Wall Street analysts who have issued ratings for Prelude Therapeutics in the last 12 months, the stock has a consensus rating of "Sell." Out of the 3 analysts, 2 have given a sell rating, and 1 has given a hold rating for PRLD.

Consensus Price Target

$4.75
-23.45% Downside
High Forecast$7.00
Average Forecast$4.75
Low Forecast$3.00

According to the 3 analysts' twelve-month price targets for Prelude Therapeutics, the average price target is $4.75. The highest price target for PRLD is $7.00, while the lowest price target for PRLD is $3.00. The average price target represents a forecasted downside of -23.45% from the current price of $6.21.

TypeCurrent Forecast
7/18/23 to 7/17/24
1 Month Ago
6/18/23 to 6/17/24
3 Months Ago
4/19/23 to 4/18/24
1 Year Ago
7/18/22 to 7/18/23
Consensus Rating
Sell
Reduce
Reduce
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
2 Buy rating(s)
Hold
1 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
Sell
2 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$4.75$5.25$5.25$10.50
Forecasted Upside-23.45% Downside25.34% Upside25.34% Upside53.85% Upside
Get Prelude Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter.

PRLD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PRLD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Prelude Therapeutics Stock vs. The Competition

TypePrelude TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
1.33
2.71
2.50
Consensus RatingSellModerate BuyModerate Buy
Predicted Upside-23.51% Downside1,207.05% Upside7.63% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/20/2024Barclays
2 of 5 stars
P. Lawson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeEqual Weight ➝ Underweight$3.00-22.48%
3/13/2024JMP Securities
2 of 5 stars
 Initiated CoverageMkt Outperform$7.00+70.73%
2/20/2024HC Wainwright
3 of 5 stars
R. Burns
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$5.00+7.99%
12/19/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeEqual Weight ➝ Underweight$10.00 ➝ $4.00-8.47%
11/21/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$8.00 ➝ $6.00-19.35%
7/29/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$9.00+62.16%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:23 PM ET.

PRLD Forecast - Frequently Asked Questions

What is Prelude Therapeutics' forecast for 2024?

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Prelude Therapeutics is $4.75, with a high forecast of $7.00 and a low forecast of $3.00.

Should I buy or sell Prelude Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prelude Therapeutics in the last twelve months. There are currently 2 sell ratings and 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" PRLD shares.

Does Prelude Therapeutics's stock price have much upside?

According to analysts, Prelude Therapeutics's stock has a predicted upside of 11.43% based on their 12-month stock forecasts.

Has Prelude Therapeutics been downgraded by Wall Street analysts recently?

Over the previous 90 days, Prelude Therapeutics's stock had 1 downgrade by analysts.

What analysts cover Prelude Therapeutics?

Prelude Therapeutics has been rated by research analysts at Barclays in the past 90 days.

Do Wall Street analysts like Prelude Therapeutics more than its competitors?

Analysts like Prelude Therapeutics less than other "medical" companies. The consensus rating for Prelude Therapeutics is Sell while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how PRLD compares to other companies.


This page (NASDAQ:PRLD) was last updated on 7/17/2024 by MarketBeat.com Staff

From Our Partners